From the Dipartimento di Biochimica e Biotecnologie
Mediche, Università di Napoli Federico II, I-80131 Napoli, Italy,
the ¶ Section of Pharmacology, Department of Oncology, Biology and
Genetics, University of Genova and Service of Pharmacology and
Neuroscience/IST, I-16132 Genova, Italy, and the
Department of Medicine, Mount Sinai School of Medicine, New
York, New York 10029-6574
Received for publication, January 29, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The cytosolic domain of the The amyloid plaques, the major pathological hallmark of
Alzheimer's disease (AD),1
contain the The c-abl proto-oncogene is the cellular counterpart
of the viral oncogene of the Abelson murine leukemia virus, and its
gene is involved in the Philadelphia chromosome translocation t (9;22) that generates the BCR-Abl fusion protein in human leukemia (for review
see Ref. 21). Abl is a nonreceptor tyrosine kinase similar to c-Src. At
the N-terminal half, Abl contains an SH3 and an SH2 domain, and
in the middle it contains a kinase domain. In contrast to Src and other
kinases, its C terminus is long and contains nuclear localization,
nuclear export signals, and domains that are able to interact with DNA
and F-actin (for recent reviews, see Refs. 22 and 23). The
intracellular distribution of Abl is very peculiar; among the various
isoforms of Abl, one (type IV) is membrane-associated and another is
soluble (type I). The latter can be found in either the cytosol
or the nucleus. The cytosolic Abl interacts with the actin cytoskeleton
(24), whereas in the nucleus it can bind DNA and other proteins
(25).
Despite the large amount of experimental data on Abl, its functions are
still not fully understood. In particular the molecular mechanisms
connecting Drosophila Abl to disabled and
enabled and mammalian Abl to mDab1 and Mena are not known.
However, the opposite effects of the mutations of the
enabled and disabled genes in Drosophila suggest that the products of these genes may be
involved in the same molecular pathway. This conjecture is in
agreement with the observations that both mDab1 and Mena participate in the protein-protein interaction network centered at the cytodomain of
APP and supports the hypothesis that c-Abl also could be involved in
the APP-centered molecular machinery. In this report we demonstrate that APP is tyrosine-phosphorylated in cells expressing a
constitutively active form of Abl. Active Abl is tightly connected to
the oligomeric complexes formed by APP, because Abl binds to the WW
domain of Fe65 and is co-immunoprecipitated with APP.
Recombinant Constructs--
The Fe65 and APP695
expression constructs have been described (5). Mouse c-Abl type IV
cDNA, cloned into the pCDNA3 vector (Invitrogen), was a kind
gift of A. Costanzo. Abl-PP expression vector and pGEX-Abl-SH2 (26)
were kindly provided by D. Barilà and G. Superti-Furga. To
generate the APPY653F, Y682F, and Y687A constructs, missense mutations
in the APP695 cDNA were introduced by the
QuikChangeTM site-directed mutagenesis kit (Stratagene)
according to manufacturer's instructions, with the following six
primer pairs (Ceinge):
5'-GGTGATGCTGAAGAAGAAACAGTTCACATCCATTCATCATGGTGTGG-3'; 5'-CCACACCATGATGAATGGATGTGAACTGTTTCTTCTTCAGCATCACC-3';
5'-CGGCTACGAAAATCCAACCGCCAAGTTCTTTGAGCAGATGC-3'; 5'-GCATCTGCTCAAAGAACTTGGCGGTTGGATTTTCGTAGCCG-3';
5'-CCAAGATGCAGCAGAACGGCTTCGAAAATCCAACCTACAAGTTCTTTG-3'; 5'-CAAAGAACTTGTAGGTTGGATTTTCGAAGCCGTTCTGCTGCATCTTGG-3'.
The recombinant constructs were sequenced by the dideoxy terminator
method with the Sequenase kit (Amersham Pharmacia Biotech) to confirm
the inserted mutations. All plasmids were propagated following standard
procedures (27) and purified on Qiagen Maxi-columns (Qiagen).
Cell Culture, Transfections, and Extract Preparation--
COS7
african green monkey kidney cells were cultured in Dulbecco's modified
minimal medium supplemented with 10% fetal calf serum at 37 °C in a
5% CO2 atmosphere. For transfection, 3 × 106 cells were electroporated at 250 microfarad and 220 V
with 5 µg each of the indicated recombinant constructs. When multiple DNAs were co-transfected, the total amount of DNA was maintained constant by the addition of pRc-CMV empty vector DNA (Invitrogen). 36 h after transfection, cells were harvested in ice-cold
phosphate-buffered saline and gently lysed in lysis buffer (50 mM Tris/HCl, pH 7.5, 150 mM sodium chloride,
0.5% Triton X-100, 10% glycerol, 50 mM sodium fluoride, 1 mM sodium vanadate) in the presence of a protease inhibitor
mixture (Complete, Roche Molecular Biochemicals). The extracts
were clarified by centrifugation at 16,000 × g at
4 °C, and the protein concentration was determined by the Bio-Rad
protein assay according to manufacturer's instructions.
Pull-down, Co-immunoprecipitation, and Kinase Assays--
The
GST fusion proteins containing the SH2 domain of Abl or the WW, PTB1,
and PTB2 domains of Fe65 were obtained by
isopropyl-thiogalactoside induction of Escherichia
coli cells harboring the corresponding constructs and purified
from the bacterial lysates with glutathione-Sepharose resin (Amersham
Pharmacia Biotech) according to the instructions of the manufacturer.
For the pull-down experiments, purified fusion proteins were used to
saturate glutathione-Sepharose beads (10 µl) and challenged to
transfected COS7 cell extracts (500 µg/sample). Unbound proteins were
removed by washing three times the beads with lysis buffer, while
retained proteins were resolved by SDS-PAGE, electroblotted to
polyvinylidene difluoride Immobilon-P membrane (Millipore) and analyzed
by Western blot with the indicated antibodies. Loading of the GST
proteins was checked by staining the filters with Ponceau S solution (Sigma).
Immunoprecipitations were carried out on COS7 lysates from transfected
cells with the following antibodies: anti-Fe65 (5); anti-APP 369 (28)
or anti-APP monoclonal antibodies 4G8 and 6E10 (Senetek PLC); anti-Abl
Ab-3 monoclonal antibody; anti-phosphotyrosine PY99 (Santa Cruz
Biotechnology); and rabbit preimmune sera and purified mouse IgGs
(Sigma), which were used as control antibodies. Immune complexes
were collected with 20 µl of protein A/G plus Sepharose (Santa Cruz),
washed three times for 5 min on a rotatory wheel at 4 °C with lysis
buffer, and separated on SDS-PAGE gels. The detection of proteins from
immunoprecipitation experiments was achieved in Western blot
experiments with the indicated above mentioned antibodies or with the
anti-APP monoclonal antibody 22C11 (Chemicon), which was followed by
enhanced chemiluminescence with the ECL kit (Amersham Pharmacia Biotech).
For the kinase assay (29), washed immune complexes, obtained with
anti-Abl sc-23 antibody (Santa Cruz) from Abl-PP-transfected COS7 cell
extracts (100 µg), were equilibrated in assay buffer (50 mM Tris/HCl, pH 7.5, 5 mM manganese chloride, 1 mM dithiothreitrol) and washed. The kinase reaction was
carried out at room temperature for 15 min by incubating the beads with
20 µl of assay buffer in the presence of 1 µg of synthetic 38-mer
APP peptide (Primm) and 5 µCi of [ Abl Interacts with the WW Domain of the Fe65 Adaptor
Protein--
It was recently hypothesized that Abl could interact with
APP through the adaptor proteins, which are known to bind to the APP
cytodomain (32). We explored the possibility that Fe65, one of the
multimodular proteins that forms complexes with APP, could be one of
the adaptors that tethers Abl to the cytodomain of APP. To address this
point we performed pull-down experiments in which GST-Fe65 fusion
proteins were used as baits to entrap Abl from extracts of COS7 cells
transfected with plasmid vectors driving the expression of type IV
mouse c-Abl or of Abl-PP, in which the mutation of two prolines of
c-Abl (Pro242 and Pro249), located
between the SH2 domain and the TK domain, results in a constitutive TK
activity (33). As shown in Fig.
1A, both PTB domains of Fe65
do not interact with Abl-PP. On the contrary, Abl-PP is
affinity-purified by the GST-Fe65 fusion protein containing the WW
domain. A similar result was observed by using the extracts from cells
transfected with c-Abl, which similarly interacts only with the
GST-Fe65-WW protein.
This interaction between Fe65 and Abl, observed in vitro,
was analyzed in extracts from COS7 cells transfected with c-Abl or
Abl-PP and immunoprecipitated with the Fe65 antibody. As shown in Fig.
1B, this experiment demonstrated that the constitutively active Abl-PP mutant is present in the proteins immunoprecipitated by
Fe65 antibody (see lane 2), whereas c-Abl is not (see
lane 9). Looking at the amino acid sequence of Abl, there is
at least one motif that can be recognized by the WW of Fe65 (PPPPPA)
located between amino acids 899 and 904 (13, 34).
The Cytosolic Domain of APP Is Tyr-phosphorylated in Cells
Expressing a Constitutively Active Form of Abl--
The Fe65-Abl-PP
interaction supports the hypothesis that Fe65 functions as a docking
site to bring Abl close to phosphorylation targets. To evaluate whether
Fe65 itself is a target of Abl TK, the same blot of Fig. 1B
was challenged with an anti-pTyr antibody. This experiment demonstrated
that Fe65 is not recognized by this antibody (see Fig. 1B,
lane 4), and therefore its tyrosine phosphorylation is
unlikely. It was documented that APP is phosphorylated on Ser and Thr
in vitro and in vivo (35, 36). However, APP was
never observed to be Tyr-phosphorylated. We analyzed the possibility that Tyr residues present in the cytodomain of APP are substrates of
Abl TK activity. To this aim, COS7 cells were transfected with an
APP695 expression vector and/or with the vector driving the expression of Abl-PP. Fig. 2A
shows that proteins immunoprecipitated using the APP antibody contained
a band of the same size as that of APP and clearly stained with an
anti-phosphotyrosine antibody only in cells that express the
constitutively active mutant form of Abl (see lane 2).
Conversely, APP is present in the proteins immunoprecipitated with the
anti-pTyr antibody, again only in cells expressing the active form of
Abl (see Fig. 2A, lanes 6 and 7).
To evaluate whether the band immunoprecipitated by the APP antibody and
stained by the anti-pTyr antibody is the consequence of a Tyr
phosphorylation of the APP cytosolic domain, a peptide was synthesized
on the basis of the C-terminal sequence of APP, common to all the APP
isoforms. This peptide was incubated in the presence of
[
There are three tyrosines located in the cytodomain of APP
(residues 653, 682, and 687 of APP695). To analyze
their involvement in the above described phenomena, we generated three
mutant APP695 expression vectors in which
Tyr653 or Tyr682 has been changed into
phenylalanine or Tyr687 has been changed into alanine.
These vectors were transfected in COS7 cells with the Abl-PP-expressing
vector. As shown in Fig. 2D, the APP-Y653F and APP-Y687A are
recognized by the anti-pTyr antibody, whereas the APP-Y682F is not;
this suggests the hypothesis that Tyr682 is the actual
target of the phosphorylation of the citodomain of APP. This result is
in agreement with the data concerning the substrate preference of
protein tyrosine kinases, indicating that c-Abl preferentially
phosphorylates proteins at the level of the YXXP
motif (37), where X are hydrophilic residues, which fits with the YENP sequence we found to be phosphorylated in APP.
APP Co-immunoprecipitates with the Active Form of Abl--
The
Western blot experiment of Fig. 2A (see lane 2),
in addition to the APP bands also shows a slower migrating band
recognized by the anti-pTyr antibody and co-immunoprecipitated by the
APP antibody. This band is present only in the samples from COS7 cells co-transfected with Abl-PP, and its size is compatible with that of Abl
itself. This possibility was analyzed in the experiments reported in
Fig. 3; panel A shows the
Western blot analysis with Abl antibody of proteins immunoprecipitated
by APP antibody that demonstrated the presence of Abl in the
immunoprecipitates. The co-immunoprecipitation of Abl with APP has been
observed also in cells not transfected with APP (see Fig.
3A, lane 3), thus suggesting that the
transfected, active Abl could also be co-immunoprecipitated with
endogenous APP751, present in significant amounts in COS7 cells. The co-immunoprecipitation of APP and Abl was confirmed in the
experiment reported in Fig. 3B, in which protein extracts from COS7 cells were immunoprecipitated with Abl antibody and blotted
with APP. Also in this case APP is present in the extract immunoprecipitated by the Abl antibody.
It was demonstrated that the various known protein tyrosine kinases
phosphorylate Tyr-containing sites that, upon phosphorylation, are
recognized by their own or closely related SH2 domains (38). This
finding suggests that the phosphorylation of the APP cytodomain at the level of the YENP motif generates a new motif, pYXXP,
that could interact with Abl SH2 domain. To examine this point, COS7 cells were transfected with APP695 or with APP695 and Abl-PP expression vectors. Total extracts from these cells were analyzed in pull-down experiments using a GST fusion protein containing the SH2 domain of
Abl. As shown in Fig. 3C, GST-Abl-SH2 protein is able to
bind to APP only in cells overexpressing active Abl, thus supporting the hypothesis that tyrosine-phosphorylated APP can form complexes with
Abl through the Abl SH2 domain. In any case, it is worth noting that
the APP Y682F mutant, which is not tyrosine-phosphorylated, still
co-immunoprecipitates with Abl, thus suggesting that in addition to an
APP-Abl interaction mediated by the SH2 domain, other complexes could
contain both APP and Abl.
We addressed the question of the possible involvement of Abl in
the protein-protein interaction network centered at the cytosolic domain of APP and found that APP is tyrosine-phosphorylated in cells
expressing a constitutively active Abl. In addition we showed that this
protein forms complexes with Fe65 and with APP itself. Our results
suggest that Fe65 could bind at the same time APP, through its PTB2
domain, and Abl, through its WW domain, thus allowing the formation of
a heterotrimeric complex. As a consequence of this interaction, active
Abl is docked close to the APP cytodomain, and this could favor the
phosphorylation of its Tyr682 (see a hypothetical model in
Fig. 4). The observed
co-immunoprecipitation of Tyr-phosphorylated APP and Abl could be the
consequence of APP-Abl interaction through the SH2 domain of
Abl, which has a high affinity for the pYXXP motif (38).
Furthermore, the phosphorylation of Tyr682 is expected to
be deleterious for the binding of the PTB domains of Fe65, X11, and
mDab1 because it was demonstrated that, at least for Fe65 and X11, this
residue is crucial for the formation of the complexes with APP (3), and
it is a hydrophobic residue in most of the known PTB binding sites
(39).
-amyloid precursor
protein APP interacts with three PTB (phosphotyrosine binding
domain)-containing adaptor proteins, Fe65, X11, and mDab1. Through
these adaptors, other molecules can be recruited at the cytodomain of
APP; one of them is Mena, that binds to the WW domain (a protein
module with two conserved tryptophans) of Fe65. The enabled
and disabled genes of Drosophila, homologues of
the mammalian Mena and mDab1 genes,
respectively, are genetic modulators of the phenotype observed in flies
null for the Abl tyrosine kinase gene. The involvement of Mena
and mDab1 in the APP-centered protein-protein interaction network
suggests the possibility that Abl plays a role in APP biology. We show
that Fe65, through its WW domain, binds in vitro and
in vivo the active form of Abl. Furthermore, in cells
expressing the active form of Abl, APP is tyrosine-phosphorylated.
Phosphopeptide analysis and site-directed mutagenesis support the
hypothesis that Tyr682 of APP695 is the target
of this phosphorylation. Co-immunoprecipitation experiments demonstrate
that active Abl and tyrosine-phosphorylated APP also form a stable
complex, which could result from the interaction of the pYENP motif of
the APP cytodomain with the SH2 domain of Abl. These results suggest
that Abl, Mena, and mDab1 are involved in a common molecular machinery
and that APP can play a role in tyrosine kinase-mediated signaling.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid peptide, which results from the proteolytic cleavage of a membrane protein known as
-amyloid precursor protein (APP) (for review see Ref. 1). The functions of APP are still poorly
understood,despite a significant amount of information concerning its
involvement in a complex protein-protein interaction network. APP is a
type I membrane protein with a small cytosolic domain that has been
shown to interact with several soluble proteins. Three of these
proteins, Fe65, X11, and mDab1, interact with APP through a PTB domain
(2-8). They have the characteristics of adaptor proteins, and thus
they could connect APP to different intracellular molecular pathways.
In addition to the PTB domain, X11 has two PDZ
(PSD-95/DlgA/ZO-1) domains and
forms oligomeric complexes with two other proteins, Munc-18 and CASK
(9, 10). Fe65 possesses two PTB domains (PTB1 and PTB2), one of which
interacts with APP (5) and the other of which interacts with LRP
(low density lipoprotein receptor-related protein), a scavenger
receptor structurally related to the low density lipoprotein receptor
(11), and with the transcription factor CP2/LSF/LBP1 (12). At
the N terminus, Fe65 possesses a WW domain, through which it forms complexes with several proteins including Mena (13), the mammalian homologue of the product of the Drosophila
enabled gene. The third PTB-containing protein that
interacts with APP is mDab1 (7, 8), the mammalian homologue of the
product of the Drosophila disabled gene. Genetic
studies have demonstrated that insects bearing the mutation of the gene
homologous to the mammalian c-abl tyrosine
kinase gene survive past morphogenesis with some defects in eye
structure, but when this mutation is associated with heterozygous or
homozygous mutations of the disabled gene, defects in the
formation of central nervous system are observed. Insects that are
homozygous for mutations in both Abl and disabled genes show
an almost complete loss of proper axonal connections (14-16). These
defects are significantly ameliorated by mutations of the
enabled gene (17, 18). The functions of the corresponding
mammalian proteins, Mena and mDab1, are probably similar. In
fact, mice lacking mDab1 show severe abnormalities in the development
of the central nervous system, including defects in migration of
neurons (19), whereas the mutation of Mena causes defects in
neurulation and commissure formation (20).
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech). The sequence of the synthetic
38-mer peptide is the following:
K6DAAVTPEERHLSKMQQNGYENPTYKFFEQMQN. Control
reactions were carried out in the absence of any protein source
and in the presence of nonspecific immune complex. The reaction
products were fractionated onto 12.5% SDS-PAGE, stained with
Coomassie R-250 (Bio-Rad), and exposed to autoradiographic films. For
phosphopeptide analysis (30, 31), the reaction products were resolved
by SDS-PAGE and transferred to an Immobilon-P polyvinylidene difluoride
membrane (Millipore). The labeled peptide band, visualized by
autoradiography, was excised and subjected to hydrolysis in the
presence of 6 N HCl for 90 min at 110 °C. Lyophilized
phospho-amino acids were resuspended in water and resolved by thin
layer chromatography on cellulose-coated glass plates (Sigma) in
propionic acid, 1 M ammonium hydroxide, 2-propanol solvent
(45/17.5/17.5, v/v/v). Detection of the labeled sample was by
autoradiography. Phospho-amino acid standards
L-phosphoserine, L-phosphothreonine, and
L-phosphotyrosine (Sigma) were run on adjacent lanes and
detected by ninhydrin spraying.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (27K):
[in a new window]
Fig. 1.
Fe65 and active Abl interact through the WW
domain of Fe65. A, glutathione-Sepharose beads were
saturated with wild type GST (lanes 2 and 7) or
with recombinant GST-Fe65 fusion proteins containing the PTB1
(lane 3), PTB2 (lane 4), or WW (lanes
5 and 8) domains of Fe65 and were incubated with
extracts from COS7 cells transfected with Abl-PP (lanes
1-5) or c-Abl (lanes 6-8) expression vectors. Bound
proteins were eluted from the resin and resolved by 8% SDS-PAGE.
Western blot (WB) was with Abl antibody. The bottom
panels (lanes 2'-5', 7', and
8') show the Ponceau S staining of the filters that
indicates the amount of each GST protein used. Lanes
1 and 6 contain 10 µg of the lysates used in the
pull-down experiments. B, protein extracts from COS7 cells
transfected with either Abl-PP (lanes 1-6) or mouse type IV
c-Abl (lanes 7-9) expression vectors were
immunoprecipitated (IP) with Fe65 antibody or, as a control,
with preimmune serum (PI) and resolved by 8% SDS-PAGE.
Western blot (lanes 1, 2, and 7-9)
was with Abl antibody. The same filter of lanes 1 and
2 was reprobed with anti-pTyr antibody (lanes 3 and 4) and then with Fe65 antibody (lanes 5 and
6). The arrowhead indicates the Abl band and the
asterisk the Fe65 bands.
View larger version (60K):
[in a new window]
Fig. 2.
APP is tyrosine-phosphorylated in cells
expressing the active form of Abl. A, extracts from COS7
cells transfected with Abl-PP and/or APP695 expression
vectors (as indicated) were immunoprecipitated (IP) with
anti-APP 369 (lanes 1-4) or anti-pTyr (lanes 6 and 7) antibodies and analyzed by Western blot
(WB) with anti-pTyr (lanes 1 and 2) or
anti-APP 369 (lanes 3-7) antibodies. Lanes 3 and
4 refer to the same filter as in lanes 1 and
2 stripped and reblotted with APP antibody. Lane
5 contains 10 µg of extract from cells trasfected with Abl-PP
and APP expression vectors. B, a 38-amino acid-long peptide
designed on the basis of the extreme C-terminal sequence common to all
of the APP isoforms was incubated in the presence of
[ -32P]ATP with immunoprecipitated proteins from COS7
cells transfected with Abl-PP expression vector. Abl antibody was used
for immunoprecipitation, and mouse IgG were used as a control. Reaction
mixtures were separated by 12.5% SDS-PAGE. Lanes 1-4 show
the Coomassie staining of the gel, and lanes
2'-4' show the autoradiography of the same gel.
Lanes 2 and 2', peptide incubated with
[
-32P]ATP; lanes 3 and 3',
peptide incubated with [
-32P]ATP and mouse
IgG-immunoprecipitated proteins; lanes 4 and 4',
peptide incubated with [
-32P]ATP and
anti-Abl-immunoprecipitated proteins. The arrowhead
indicates the migration of peptide band. C, the
32P-labeled peptide was hydrolyzed, and the resulting amino
acids were separated by thin layer chromatography as described under
"Experimental Procedures." The migration of the phospho-amino acid
standard is reported: pTyr; pThr, phosphothreonine; and
pSer, phosphoserine. D, extracts from COS7 cells
transfected with Abl-PP and with wild type APP695
(lanes 1 and 5) or mutants APP Y653F
(lanes 2 and 6), APP Y682F (lanes 3 and 7), or APP Y687A (lanes 4 and 8)
expression vectors were immunoprecipitated with anti-APP antibodies 4G8
and 6E10 and analyzed by Western blot with anti-pTyr antibody
(lanes 1-4). The same filter was reprobed with anti-APP 369 antibody (lanes 5-8).
-32P]ATP with an Abl-immunoprecipitated extract of
COS7 cells expressing Abl-PP. Fig. 2B shows the
autoradiography of the SDS-PAGE gel and the peptide results to be
32P-labeled only when incubated with the proteins
immunoprecipitated with the Abl antibody and not with the proteins
immunoprecipitated with unrelated antibodies. The labeled band was
transferred onto a polyvinylidene difluoride filter, and the peptide
was hydrolyzed as described under "Experimental Procedures." The
resulting amino acids were separated by thin layer chromatography, and
32P-labeled amino acids were detected by autoradiography.
Fig. 2C shows that the only 32P-labeled residue
found in the hydrolyzed peptide was phosphotyrosine.
View larger version (40K):
[in a new window]
Fig. 3.
APP695
co-immunoprecipitates with active Abl-PP. A, extracts
from COS7 cells transfected with Abl-PP and/or with wild type
APP695 expression vectors, as indicated, were
immunoprecipitated (IP) with APP 4G8 and 6E10 monoclonal
antibodies (lanes 2-5) or, as a control, with mouse IgG
(lanes 6-9) and analyzed by Western blot with Abl antibody.
Lane 1 shows the Western blot analysis with Abl antibody of
10 µg of Abl-PP expressing COS7 cell extract. B, extracts
from COS7 cells transfected with Abl-PP and/or with wild type
APP695 expression vectors, as indicated, were
immunoprecipitated with Abl antibody and analyzed by Western blot with
APP 22C11 monoclonal antibody. Lane 1 shows the Western blot
analysis with APP antibody of 10 µg of APP expressing COS7 cell
extract. C, glutathione-Sepharose beads were saturated with
wild type GST (lanes 3 and 5) or with recombinant
GST-Abl-SH2 fusion protein (lanes 4 and 6)
and were incubated with extracts from COS7 cells transfected with
APP695 alone (lanes 3 and 4) or with APP695 plus
Abl-PP (lanes 5 and 6). Bound proteins were
eluted from the resin and resolved by 8% SDS-PAGE. Western blot
(WB) was with APP antibody 369. Lanes 1 and 2 contain 10 µg of the lysates used in the pull-down experiments.
The bottom panels (lanes
3'-6') show the Ponceau S staining of the filters that
indicates the amount of each GST protein used.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (19K):
[in a new window]
Fig. 4.
Proposed model for the recruitment of active
Abl to the APP cytodomain. A, Fe65 could bind
transiently both APP, through its PTB2 domain, and active Abl, through
its WW domain, thus allowing the formation of a heterotrimeric complex.
As a consequence of this interaction, active Abl could
phosphorylate the Tyr682 residue of APP. mDab1 and Mena are
expected to compete with Abl for the binding to APP. B, once
phosphorylated, APP could directly interact with the SH2 domains of
various proteins including Abl itself. The phosphorylation of
Tyr682 is expected to be deleterious for the binding of the
PTB domains of Fe65 to APP because this requires a hydrophobic amino
acid in that position.
As reported in Fig. 4, there are several lines of evidence suggesting that Abl, mDab1, and Mena are involved in common molecular machineries. It was, in fact, demonstrated that mDab1 binds through its PTB domain with the cytosolic domain of APP (7, 8) and that Mena interacts with the WW domain of Fe65 (13), which, in turn, interacts with APP. Considering the results reported in this paper, it can be hypothesized that Abl, mDab1, and Mena compete for the anchoring to the same intracellular site: mDab1 by competing with Fe65 for the binding to the cytodomain of APP; and Abl and Mena by competing for the binding to the WW domain of Fe65 (Fig. 4).
It is worth noting that the Tyr682 of human
APP695 and the YENP motif are both conserved among all the
known APPs in primates, rodents, Drosophila, and
Caenorhabditis and are present also in the APP-related
proteins APLP1 and APLP2. Considering that the overall sequence
identity between Drosophila APP (Appl) and the mammalian
APPs is less than 30%, the 100% conservation of the cytosolic motif
containing the phosphorylated tyrosine suggests that it plays a key
functional role. This means that the understanding of the molecular
basis of the different phenotypes observed in insects bearing mutations
of Drosophila Abl (DAbl) and/or
disabled and/or enabled should also take into
account the involvement of APP. Appl null flies show
behavioral defects that are rescued by human APP, and the possible
correlation with the defects caused by DAbl,
disabled, and enabled gene mutations is not
apparent. However, one could gain better insight by the analysis of the phenotypes of insects bearing combined mutations of Appl
with the other three genes. For example, the effects of disabled gene mutation on the Abl /
flies also could be the consequence of the
direct interaction of these two proteins with APP, whereas the
amelioration observed in Drosophila Abl
/
disabled
/
following the mutation of the
enabled gene could be also based on the competition between
the enabled and DAbl gene products for the
binding to Appl through Drosophila Fe65.
Although the WW domain of Fe65 interacts in vitro with both c-Abl and Abl-PP, only the complexes between Fe65 and the active form of Abl, and not those with the wild type c-Abl, were found in cell extracts. This effect could be due to a lower amount of c-Abl than Abl-PP available for the formation of the in vivo complexes; or it could be due to a low affinity of c-Abl for the WW domain of Fe65 so that, in vivo, it cannot form a significant number of complexes with Fe65 because of the competition of the other ligands of the WW domain of this protein. Furthermore, active Abl probably has a different conformation than c-Abl, thus acquiring a higher affinity for the WW domain. On the contrary, the APP-Abl direct interaction probably requires an active Abl, because the binding is based on a pTyr-SH2 interaction.
It has been hypothesized often that APP could have some role in signaling, and in a recent review article, Bothwell and Giniger (32) suggested the possibility that intracellular signaling could be involved in the development of AD. Their hypothesis takes into account the numerous reports on various proteins that could be involved in the pathogenesis of AD and suggests a role for c-Abl as a modulator of APP biology. Our results support their hypothesis. A point that deserves attention, besides those discussed in the mentioned review article, concerns the possible involvement of p73 in the molecular machinery under examination. In fact, this protein is a key regulator of apoptosis that binds to and is activated by Abl as a response to DNA damage (40-42). An isoform of p73 functions as an anti-apoptotic protein in developing neurons (43), and the role of its phosphorylation by Abl has not been addressed. The finding that active Abl binds to APP suggested an examination of the possible regulatory effects of this binding on the p73 phosphorylation by Abl and the consequences on this regulation of the enhanced APP proteolytic processing characteristic of AD.
Our results support the hypothesis that Fe65 connects Abl to the
APP-centered molecular machinery. However, other possible roles of the
Fe65·Abl complex should be examined, as for example those
suggested by the observation that both Fe65 and Abl, further than in
the cytoplasm, are also localized in the nucleus (24, 44).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank A. Costanzo, D. Barilà, and G. Superti-Furga for expression vectors and M. Santoro for helpful discussion.
![]() |
FOOTNOTES |
---|
* This work was supported by grants from the V Framework program (Contract QLK6-1999-02238), European Union, the Consiglio Nazionale delle Ricerche-Italy "Programma Biotecnologie MURST L.95/95," and the "Progetto strategico Basi biologiche delle malattie degenerative del Sistema Nervoso Centrale" (to T. R.), the Alzheimer Association (RG 99-1670), and the Human Frontier Science Program Organization (Grant RG 234 to M. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported by Biogem fellowships.
** To whom correspondence should be addressed: Dipartimento di Biochimica e Biotecnologie Mediche, Via S. Pansini 5, I-80131 Napoli, Italy. Tel.: +390817463131; Fax: +390817464359; E-mail: russot@dbbm.unina.it.
Published, JBC Papers in Press, February 21, 2001, DOI 10.1074/jbc.M100792200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
AD, Alzheimer's disease;
APP, -amyloid precursor protein;
GST, glutathione S-transferase;
PTB, phosphotyrosine binding domain;
pTyr, phosphotyrosine;
PAGE, polyacrylamide gel electrophoresis;
SH2/3, Src homology domains 2 and
3;
TK, tyrosine kinase.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Selkoe, D. J. (1999) Nature 369 (suppl.), A23-A31 |
2. |
Fiore, F.,
Zambrano, N.,
Minopoli, G.,
Donini, V.,
Duilio, A.,
and Russo, T.
(1995)
J. Biol. Chem.
270,
30853-30856 |
3. | Borg, J. P., Ooi, J., Levy, E., and Margolis, B. (1996) Mol. Cell. Biol. 16, 6229-6241[Abstract] |
4. |
Bressler, S. L.,
Gray, M. D.,
Sopher, B. L.,
Hu, Q. B.,
Hearn, M. G.,
Pham, D. G.,
Dinulos, M. B.,
Fukuchi, K. I.,
Sisodia, S. S.,
Miller, M. A.,
Disteche, C. M.,
and Martin, G. M.
(1996)
Hum. Mol. Genet.
5,
1589-1598 |
5. |
Zambrano, N.,
Buxbaum, J. D.,
Minopoli, G.,
Fiore, F.,
De Candia, P.,
De Renzis, S.,
Faraonio, R.,
Sabo, S.,
Cheetham, J.,
Sudol, M.,
and Russo, T.
(1997)
J. Biol. Chem.
272,
6399-6405 |
6. | McLoughlin, D. M., and Miller, C. C. J. (1996) FEBS Lett. 397, 197-200[CrossRef][Medline] [Order article via Infotrieve] |
7. |
Homayouni, R.,
Rice, D. S.,
Sheldon, M.,
and Curran, T.
(1999)
J. Neurosci.
19,
7507-7515 |
8. |
Howell, B. W.,
Lanier, L. M.,
Frank, R.,
Gerler, F. B.,
and Cooper, J. A.
(1999)
Mol. Cell. Biol.
19,
5179-5188 |
9. |
Borg, J. P.,
Straight, S. W.,
Kaech, S. M.,
de Taddeo-Borg, M.,
Kroon, D. E.,
Karnak, D.,
Turner, R. S.,
Kim, S. K.,
and Margolis, B.
(1998)
J. Biol. Chem.
273,
31633-31636 |
10. |
Borg, J. P.,
Lopez-Figueroa, M. O.,
de Taddeo-Borg, M.,
Kroon, D. E.,
Turner, R. S.,
Watson, S. J.,
and Margolis, B.
(1998)
J. Neurosci.
19,
1307-1316 |
11. |
Trommsdorff, M.,
Borg, J-P.,
Margolis, B.,
and Herz, J.
(1998)
J. Biol. Chem.
273,
33556-33560 |
12. |
Zambrano, N.,
Minopoli, G.,
De Candia, P.,
and Russo, T.
(1998)
J. Biol. Chem.
273,
20128-20133 |
13. |
Ermekova, K-S.,
Zambrano, N.,
Linn, H.,
Minopoli, G.,
Gertler, F.,
Russo, T.,
and Sudol, M.
(1997)
J. Biol. Chem.
272,
32869-32874 |
14. | Gertler, F. B., Bennett, R. L., Clark, M. J., and Hoffmann, F. M. (1989) Cell 58, 103-113[Medline] [Order article via Infotrieve] |
15. | Henkemeyer, M., West, S. R., Gertler, F. B., and Hoffmann, F. M. (1990) Cell 63, 949-960[Medline] [Order article via Infotrieve] |
16. | Gertler, F. B., Hill, K. K., Clark, M. J., and Hoffmann, F. M. (1993) Genes Dev. 7, 441-453[Abstract] |
17. | Gertler, F. B., Doctor, J. S., and Hoffmann, F. M. (1990) Science 248, 857-860[Medline] [Order article via Infotrieve] |
18. | Gertler, F. B., Comer, A. R., Juang, J. L., Ahern, S. M., Clark, M. J., Liebl, E. C., and Hoffmann, F. M. (1995) Genes Dev. 9, 521-533[Abstract] |
19. | Howell, B. W, Hawkes, R., Soriano, P., and Cooper, J. A. (1997) Nature 389, 733-737[CrossRef][Medline] [Order article via Infotrieve] |
20. | Lanier, L. M., Gates, M. A., Witke, W., Menzies, A. S., Wehman, A. M., Macklis, J. D., Kwiatkowski, D., Soriano, P., and Gertler, F. B. (1999) Neuron 22, 313-325[Medline] [Order article via Infotrieve] |
21. | Cortes, J. E., Talpaz, M., and Kantarjian, H. (1996) Am. J. Med. 100, 555-570[CrossRef][Medline] [Order article via Infotrieve] |
22. | Van Etten, R. A. (1999) Trends Cell Biol. 9, 179-186[CrossRef][Medline] [Order article via Infotrieve] |
23. | Shaul, Y. (2000) Cell Death Differ. 7, 10-16[CrossRef][Medline] [Order article via Infotrieve] |
24. | Van Etten, R. A., Jackson, P., and Baltimore, D. (1989) Cell 58, 669-678[Medline] [Order article via Infotrieve] |
25. |
Miao, Y-J.,
and Wang, J. Y. J.
(1996)
J. Biol. Chem.
272,
8905-8911 |
26. |
Barilà, D.,
Mangano, R.,
Gonfaloni, S.,
Kretzschmar, J.,
Moro, M.,
Bohmann, D.,
and Superti-Furga, G.
(2000)
EMBO J.
19,
273-281 |
27. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor University Press, Cold Spring Harbor, NY |
28. | Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernik, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6003-6006[Abstract] |
29. |
Tauchi, T.,
Miyazawa, K.,
Feng, G. S.,
Broxmeyer, H. E.,
and Toyama, K.
(1997)
J. Biol. Chem.
272,
1389-1394 |
30. | Duclos, B., Marcandier, S., and Cozzone, A. J. (1991) Methods Enzymol. 201, 10-21[Medline] [Order article via Infotrieve] |
31. | Kamps, M. P. (1991) Methods Enzymol. 201, 21-27[Medline] [Order article via Infotrieve] |
32. | Bothwell, M., and Giniger, E. (2000) Cell 102, 271-273[Medline] [Order article via Infotrieve] |
33. | Barilà, D., and Superti-Furga, G. (1998) Nat. Genet. 18, 280-282[Medline] [Order article via Infotrieve] |
34. |
Kay, B. K.,
Williamson, M. P.,
and Sudol, M.
(2000)
FASEB. J.
14,
231-241 |
35. | Suzuki, T., Oishi, M., Marshak, D. M., Czernik, A. J., Nairn, A. C., and Greengard, P. (1994) EMBO J. 13, 1114-1122[Abstract] |
36. | Suzuki, T., Ando, K., Isohara, T., Oishi, M., Lim, G. S., Satoh, Y., Wasco, W., Tanzi, R. E., Nairn, A. C., Greengard, P., Gandy, S. E., and Kirino, Y. (1997) Biochemistry 36, 4646-4649 |
37. | Songyang, Z., Carraway, K. L., III, Eck, M. J., Harrison, S. C., Feldman, R. A., Mohammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng, C., Lorenzo, M. J., Ponder, B. A. J., Mayer, B. J., and Cantley, L. C. (1995) Nature 273, 536-539 |
38. | Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., and Lechleider, R. J. (1993) Cell 72, 767-778[Medline] [Order article via Infotrieve] |
39. | van der Geer, P., and Pawson, T. (1995) Trends Biochem. Sci. 20, 277-280[CrossRef][Medline] [Order article via Infotrieve] |
40. | Gong, JG, Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., and Wang, J. Y. J. (1999) Nature 399, 806-809[CrossRef][Medline] [Order article via Infotrieve] |
41. | Agami, R., Blandino, G., Oren, M., and Shaul, Y. (1999) Nature 399, 809-8813[CrossRef][Medline] [Order article via Infotrieve] |
42. | Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R., and Kufe, D. (1999) Nature 399, 814-817[CrossRef][Medline] [Order article via Infotrieve] |
43. |
Pozniak, C.,
Radinovic, S.,
Yang, A.,
McKeon, F.,
Kaplan, D. R.,
and Miller, F. D.
(2000)
Science
289,
304-306 |
44. |
Minopoli, G.,
de Candia, P.,
Bonetti, A.,
Faraonio, R.,
Zambrano, N.,
and Russo, T.
(2001)
J. Biol. Chem.
276,
6545-6550 |